Pharmaron Beijing Co., Ltd. (SHE:300759)
China flag China · Delayed Price · Currency is CNY
40.90
-0.70 (-1.68%)
Nov 17, 2026, 3:04 PM CST

Pharmaron Beijing Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Cash & Equivalents
3,1321,0171,6905,9191,4973,544
Short-Term Investments
-885.65257.27179.36613.241,080
Trading Asset Securities
901.88714.071,115594.33745.361,555
Cash & Short-Term Investments
4,0342,6173,0626,6932,8566,178
Cash Growth
76.94%-14.54%-54.24%134.33%-53.77%60.37%
Accounts Receivable
3,5633,1882,8712,6362,2141,424
Other Receivables
123.7858.2126.8980.9871.1692.43
Receivables
3,6863,2462,9982,7172,2861,516
Inventory
2,2051,4721,1171,0131,041680.04
Other Current Assets
1,658442.71430.73451.33352.82269.05
Total Current Assets
11,5837,7787,60810,8746,5368,644
Property, Plant & Equipment
13,05111,97010,79810,0628,4645,811
Long-Term Investments
1,5201,158883.041,0051,008762.67
Goodwill
3,4833,5862,7612,7812,6882,096
Other Intangible Assets
1,2421,197791789.06802.53692.94
Long-Term Deferred Tax Assets
275.68262.91192.68153.2258.7915.6
Long-Term Deferred Charges
573.26617.99678.5520.47496.38171.6
Other Long-Term Assets
513.12465.28155.44267.09438.91195.99
Total Assets
32,24127,09423,92726,47720,49318,389

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Accounts Payable
866.91606.59477.09412.22406.35315.53
Accrued Expenses
945.571,050853.93805.65784.92626.21
Short-Term Debt
1,3331,265764.97577.07662.77421.76
Current Portion of Long-Term Debt
3,5783,501282.34150.3474.9460.54
Current Portion of Leases
-122.7149.51185.32164.0395.29
Current Income Taxes Payable
197.72133.2160.08184.55145.8781.34
Current Unearned Revenue
1,225960.61834.86740.87832.14679.62
Other Current Liabilities
3,023724.9701.23598.47841.4701.7
Total Current Liabilities
11,1688,3644,2243,6543,9122,982
Long-Term Debt
2,1341,7724,3778,2004,4544,423
Long-Term Leases
421.41379.42401.31585.2760.51284.34
Long-Term Unearned Revenue
441.42442.86409.98391.71152.38149.44
Long-Term Deferred Tax Liabilities
485.44397.15291.87290.04261.01173.3
Other Long-Term Liabilities
---117.58112.0981.56
Total Liabilities
14,65111,3559,70513,2399,6538,094

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Common Stock
1,8371,7791,7781,7871,191794.18
Additional Paid-In Capital
5,7744,9505,0085,2225,2546,008
Retained Earnings
9,4508,5687,2575,8184,5743,554
Treasury Stock
-99.6-304.89-416.27-463.45-668.04-301.83
Comprehensive Income & Other
-71.8371.8-7.76193.72197.2674.15
Total Common Equity
16,89015,06413,61912,55710,54910,129
Minority Interest
699.61674.38603.54681.25291.25166.07
Shareholders' Equity
17,59015,73914,22313,23810,84010,295
Total Liabilities & Equity
32,24127,09423,92726,47720,49318,389

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Total Debt
7,4667,0405,9759,6986,1175,285
Net Cash (Debt)
-3,433-4,423-2,913-3,005-3,260893.04
Net Cash Growth
------68.12%
Net Cash Per Share
-1.89-2.50-1.64-1.69-1.840.49
Filing Date Shares Outstanding
1,8261,8301,7661,7871,7871,787
Total Common Shares Outstanding
1,8261,7711,7661,7871,7871,787
Working Capital
414.69-585.843,3847,2202,6245,662
Book Value Per Share
9.258.517.717.035.905.67
Tangible Book Value
12,16610,28210,0688,9877,0587,340
Tangible Book Value Per Share
6.665.815.705.033.954.11
Buildings
-5,6474,9213,9713,3472,473
Machinery
-7,5956,2745,1494,2652,919
Construction In Progress
-2,3652,2542,6331,6711,374